Vera Therapeutics (NASDAQ:VERA – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ...

Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Vera Therapeutics in a note issued to ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients ...